Israel Agrees to Review BioCryst’s Marketing Request for Orladeyo

Israel Agrees to Review BioCryst’s Marketing Request for Orladeyo

297244

Israel Agrees to Review BioCryst’s Marketing Request for Orladeyo

The Israeli Ministry of Health has agreed to review, under an accelerated process, a marketing application for Orladeyo (berotralstat), BioCryst Pharmaceuticals’ oral preventive treatment for hereditary angioedema (HAE) attacks, in patients 12 and older. Neopharm Israel, one of the leading pharmaceutical companies in Israel, will distribute Orladeyo, if it’s approved. This follows a distribution and supply agreement granting Neopharm Ltd. the exclusive rights to commercialize the therapy in Israel and in the Palestinian Authority. “Neopharm is…

You must be logged in to read/download the full post.